Fig. 4.

Lifetime healthcare costs for all patients with SCD with recurrent VOCs^a, the subgroup of patients who continued to experience ≥ 2 VOCs per year during the variable-length follow-up^b, and matched controls^c. ^aAnnual costs for patients with SCD with recurrent VOCs per age group were $24,697 (age 0–5 years [n = 503]), $33,499 (age 6–10 years [n = 473]), $54,715 (age 11–15 years [n = 504]), $81,875 (age 16–20 years [n = 657]), $95,082 (age 21–25 years [n = 436]), $83,612 (age 26–30 years [n = 247]), $98,964 (age 31–35 years [n = 208)], $82,573 (age 36–40 years [n = 143)], $105,580 (age 41–50 years [n = 152]), and $102,262 (age ≥ 51 years [n = 97]). ^bAnnual costs for patients in the ≥ 2 VOCs PPPY subgroup per age group were $34,191 (age 0–5 years [n = 234]), $48,581 (age 6–10 years [n = 252]), $68,295 (age 11–15 years [n = 341]), $99,588 (age 16 to 20 years [n = 506]), $104,578 (age 21 to 25 years [n = 367]), $101,813 (age 26–30 years [n = 194]), $121,490 (age 31–35 years [n = 152]), $98,856 (age 36–40 years [n = 102]), $135,580 (age 41–50 years [n = 103]), and $129,340 (age ≥ 51 years [n = 59]). ^cAnnual costs for matched controls per age group were $1423 (age 0–5 years [n = 2725]), $2334 (age 6–10 years [n = 2384]), $2947 (age 11–15 years [n = 2860]), $5517 (age 16–20 years [n = 2257]), $6040 (age 21–25 years [n = 2261]), $5523 [age 26–30 years [n = 1259]), $4351 (age 31–35 years [n = 1016]), $3984 (age 36–40 years [n = 405]), $7432 (age 41–50 years [n = 828]), and $8253 (age ≥ 51 years [n = 727]). K thousand; M million; SCD sickle cell disease; VOC vaso-occlusive crisis